WIW. Inauen

W. Inauen

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


W. Inauen has a total of 18 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Effects of ABT‐229, a motilin agonist, on acid reflux, oesophageal motility and gastric emptying in patients with gastro‐oesophageal reflux disease

    by P. Netzer, B. Schmitt, W. Inauen

    Summary: Aim : The effect of ABT‐229, a new macrolide with no antibacterial activity, on gastro‐oesophageal reflux, oesophageal motility and gastric emptying in patients with gastro‐oesophageal reflux disease was investigated.Methods : Twenty‐one patients were treated with a placebo and ABT‐229 (2.5, 5 or 10 mg b.d.) in a randomized, incomplete crossover study design. Ambulatory 24‐h pH manometry was performed and gastric emptying was assessed by the 13C‐octanoic acid breath test on the seventh day of treatment.Results : A significant decrease was found in the mean (± s.e.) percentage of reflux time (intra‐oesophageal pH < 4) for ABT‐229 5 mg b.d. and 10 mg b.d., but not for 2.5 mg b.d., compared with placebo. For ABT‐229 5 mg, it was 8.5 ± 0.5% vs. 10.7 ± 0.7% (P < 0.038) and, for ABT‐229 10 mg, it was 6.6 ± 0.5% vs. 8.4 ± 0.5% (P < 0.019). There were no significant differences in any of the analysed manometric parameters. In addition, the gastric half‐emptying time for all doses of ABT‐229 did not differ significantly from that after placebo.Conclusions : ABT‐229 is able to reduce slightly, but significantly, acid reflux in patients with gastro‐oesophageal reflux disease. This effect does not appear to be due to a measurable improvement in oesophageal motility or gastric emptying.


  • Open Access

    Influence of pantoprazole on oesophageal motility, and bile and acid reflux in patients with oesophagitis

    by P. Netzer, A. Gut, R. Brundler, C. Gaia, F. Halter, W. Inauen

    Background: Reflux of duodeno‐gastric juice into the oesophagus appears to be involved in the pathogenesis of both reflux oesophagitis and oesophageal adenocarcinoma. Although proton pump inhibitors have been shown to decrease acid reflux and heal oesophagitis, their effect on biliary reflux and motility is less clear. Aim: To investigate whether pantoprazole also reduces bile reflux and whether this is paralleled by a change in oesophageal motility. Methods: Combined 24‐h measurements of intraoesophageal bilirubin concentration, pH and pressure were performed in 18 symptomatic patients with endoscopically proven reflux oesophagitis before and on day 28 of treatment with pantoprazole, 40 mg/day, under standardized conditions. A reflux symptom score was determined initially and every 2 weeks thereafter. After 56 days on medication, a control endoscopy was performed. Results: The symptom score and the acid and bile reflux improved significantly, whereas the motility parameters did not change during the study period. Helicobacter pylori‐positive patients had a significantly higher bile reflux time (32.1 ± 4.3%) than H. pylori‐negative patients (16.3 ± 3.1%) (P=0.009). The endoscopic healing rate was 89%. The cough symptoms disappeared in three of four patients. Conclusions: The proton pump inhibitor pantoprazole decreases both acid and bile reflux. The decrease of bile reflux cannot be explained by increased oesophageal clearance as oesophageal motility did not improve with therapy. Interestingly, H. pylori infection of the stomach was associated with higher levels of oesophageal bile reflux.


    • 1 March 1997
      • Vol. 92  (3) , 400-6

    Self-expanding metal stents in malignant esophageal obstruction: a comparison between two stent types.

    by A Schmassmann, C Meyenberger, J Knuchel, J Binek, F Lammer, B Kleiner, S Hürlimann, W Inauen, B Hammer, U Scheurer, et al.

    Self-expanding metal stents are a promising alternative in the palliation of malignant esophageal obstruction, but the relative value of different stent types is not well established. During a 3-year enrollment period in four different centers, 82 consecutive patients with malignant dysphagia without tumor recurrence after surgery or esophagorespiratory fistulas received either an uncovered Wallstent (44 patients) or a knitted nitinol stent (38 patients). Age (median: 79 yr), sex (F:M = 33:67), dysphagia score (median: 3), Karnofsky score (median: 53), body mass index (median: 19), type of pretreatment, tumor stage, stricture length (median: 5.4 cm), and stricture location were comparable in both stent groups. After stent placement, median dysphagia score improved markedly in both groups by two points. Procedure-related mortality (16 vs 0%; p < 0.01), early complication rate (32 vs 8%; p < 0.01), and severe persistent pain after stent placement (23 vs 0%; p < 0.002) were higher in the Wallstent compared with the knitted nitinol stent group. In contrast, stent dysfunction (7 vs 32%; p < 0.005), reintervention rate (9 vs 34%; p < 0.005), and costs were lower in the Wallstent compared with the nitinol stent group. In malignant esophageal obstruction, both stents markedly improved dysphagia. Uncovered Wallstents seem to cause more early severe complications than knitted nitinol stents. In contrast, stent dysfunction, reintervention rate, and costs appear to be higher in the nitinol stent group.


    • 1 June 1996
      • Vol. 91  (6) , 1173-80

    Effect of Rennie Liquid versus Maalox Liquid on intragastric pH in a double-blind, randomized, placebo-controlled, triple cross-over study in healthy volunteers.

    by S Hürlimann, K Michel, W Inauen, F Halter

    Despite years of successful use of calcium-containing antacids in acid-related disease, allegations of gastric rebound following their intake has brought these agents into disrepute. By assessing intragastric acidity over the 24-h period, we evaluated whether antacids induce a clinically relevant acid rebound. Twelve healthy volunteers were assigned to a double-blind, placebo-controlled, triple cross-over comparison of placebo, Maalox Liquid, and a calcium-containing antacid, Rennie Liquid. The two antacids had identical neutralizing capacity. Each drug was administered at standard doses q.i.d 1 h after the main meals (at 1000, 1400, and 1900 h) and at bedtime (2300 h). Intragastric acidity was monitored by continuous ambulatory 24-h pH-metry on 3 separate days with a wash-out period of 1 wk. Special attention was given to the acidity of pre-determined postantacid time intervals during the day and night. Both antacids led to a significant increase of the median 24-h pH and the median pH of the first postantacid hour, compared with placebo. Neither Rennie Liquid nor Maalox Liquid led to a drop of intragastric pH during the putative acid rebound time (2nd and 3rd postantacid hr and at night). A marginal increase in serum calcium and gastrin concentration with Rennie Liquid, and magnesium concentration with Maalox Liquid, were observed. No gastric acid rebound was detected with the calcium carbonate-containing antacid, Rennie Liquid, or with Maalox Liquid at standard doses. An identical increase of intragastric pH was achieved with Rennie Liquid and Maalox Liquid during the first postantacid hour and the entire 24-h period.